US-based ViewRay has secured the Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its MRIdian System.

MRIdian is a clinical MRI-guided radiation therapy system, which integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation.

It is based on a patented combination of magnetic resonance imaging (MRI) and radiation therapy delivery technology, to offer high-quality pretreatment images and continuous soft-tissue imaging during treatment while the beam is on.

"We expect the MRIdian system to be well received and for patients throughout Japan to benefit from more precise, personalised radiation treatment."

The system provides clinicians with a clear view of the target, such as the soft tissue in real time, which enables them to see the site where the radiation dose is actually being delivered, thereby allowing them to adjust the therapy in accordance with the patient's anatomy.

With MRIdian, the procedure can be done without exposing the patient to the additional ionising radiation that is common with other imaging modalities.

ViewRay president and CEO Chris Raanes said: "Together with our partner ITOCHU Corporation, we are pleased to be able to bring the advantages of MRI-guided radiation treatment to cancer patients in Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Not only is Japan a large market, its radiation oncologists have traditionally been early adopters of advanced medical technologies.

"We expect the MRIdian system to be well received and for patients throughout Japan to benefit from more precise, personalised radiation treatment."

Japanese general trading company, ITOCHU will represent ViewRay in Japan.

The Japanase approval of ViewRay's MRIdian System is believed to expand its geographical footprint.